瑞舒伐他汀联合依达拉奉对急性脑梗死治疗效果及炎症因子影响.docVIP

瑞舒伐他汀联合依达拉奉对急性脑梗死治疗效果及炎症因子影响 　　[摘要] 目的 分析瑞舒伐他汀联合依达拉奉对急性脑梗死患者治疗效果及炎症因子的影响。 方法 方便选取2015年3月―2016年2月淄博市中西医结合医院收治的86例急性脑梗死患者，按随机数字表法分成观察组和对照组，每组43例。对照组采用依达拉奉进行治疗，观察组在对照组的基础上给予瑞舒伐他汀。对比两组治疗效果及治疗前、后炎症因子水平。结果 观察组治疗的总有效率为95.35%明显高于对照组的81.40%（P0.05）；观察组治疗后MMP-9及hs-CRP分别为（29.32±12.61）ng/L和（15.54±8.86）mg/L，低于对照组的（38.81±14.29）ng/L和（21.93±9.72）mg/L（P0.05）。结论 瑞舒伐他汀联合依达拉奉能有效的提高对急性脑梗死的治疗效果，并降低炎症因子水平。 　　[关键词] 瑞舒伐他汀；依达拉奉；急性脑梗死 　　[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2017）01（c）-0117-03 　　Effect of Rosuvastatain and Edaravone on the Treatment Effect of Acute Cerebral Infarction and Inflammatory Factor 　　FENG Jian-wen 　　Department of Phamarcy， Hospital of Integrated TCM and Western Medicine， Zibo， Shandong Province， 255026 China 　　[Abstract] Objective To analyze the effect of rosuvastatain and edaravone on the treatment effect of acute cerebral infarction and inflammatory factor. Methods Convenient selection 86 cases of patients with acute cerebral infarction admitted and treated in our hospital from March 2015 to February 2016 were randomly divided into two groups with 43 cases in each， the control group were treated with edaravone， while the observation group were treated with rosuvastatain on the basis of the control group， and the treatment effect and inflammatory factor level before and after treatment were compared between the two groups. Results The total treatment effective rate in the observation group was obviously higher than that in the control group，（95.35% vs 81.40%）（P0.05）， and the MMP-9 and hs-CRP before treatment between the observation group and the control group had no statistical significance， [（58.36±14.59）ng/L，（31.28±10.55）mg/L vs （57.26±15.12）ng/L， （30.59±10.64）mg/L]， and the MMP-9 and hs-CRP after treatment in the observation group were lower than those in the control group，[（29.32±12.61）ng/L， （15.54±8.86）mg/L vs （38.81±14.29）ng/L， （21.93±9.72）mg/L]（P0.05）. Conclusion Rosuvastatain and edaravone can effectively improve the treatment effect of acute cerebral